Study title:
Schellong-G, Poetter-R, Braemswig-J, Wagner-W, Prott-F-J, Doerffel-W, Koerholz-D, Mann-G, Rath-B, Reiter-A, Weissbach-G, Riepenhausen-M, Thiemann-M, Schwarze-E-W.
Department of Pediatric Hematology and Oncology, University
Children's Hospital, Germany. schellon@uni-muenster.de.
High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German- Austrian Pediatric Hodgkin's Disease Study Group.
Journal of clinical oncology : official journal of the American
Society of Clinical Oncology, {J-Clin-Oncol}, Dec 1999, vol. 17, no. 12, p. 3736-44, ISSN: 0732-183X.Schellong-G, Poetter-R, Braemswig-J, Wagner-W, Prott-F-J, Doerffel-W, Koerholz-D, Mann-G, Rath-B, Reiter-A, Weissbach-G, Riepenhausen-M, Thi...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|